DATA GRAPHICS | Market Access
SMA sales: Spinraza, Zolgensma and Evrysdi converge
The ASO, gene therapy and small molecule are sharing similar portions of the $1.3B market
July 28, 2023 11:23 PM UTC
The rapid rise in global sales of Roche’s Evrysdi took a pause last quarter, with the small molecule not yet eclipsing Biogen’s Spinraza. Zolgensma sales remained steady. All three treatments for spinal muscular dystrophy are bringing in roughly similar revenue.
Even with its sales falling 1.4% quarter-over-quarter to $437 million in 2Q23, Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) remains the market leader, as sales of Evrysdi risdiplam from Roche (SIX:ROG; OTCQX:RHHBY) also dipped in 2Q23, from $397 million to $382 million...